Circulation Reports

Journal Information
EISSN : 2434-0790
Current Publisher: Japanese Circulation Society (10.1253)
Total articles ≅ 235
Filter:

Latest articles in this journal

Keiko Sumimoto, Hidekazu Tanaka, Jun Mukai, Kentaro Yamashita, Yusuke Tanaka, Ayu Shono, Makiko Suzuki, Shun Yokota, Kensuke Matsumoto, Yu Taniguchi, et al.
Circulation Reports, Volume 2, pp 625-629; doi:10.1253/circrep.cr-20-0094

Madoka Ihara, Yuhei Nojima, Nobuyuki Koh, Hidenori Adachi, Tetsuya Kurimoto, Keita Okayama, Yasushi Sakata, Shinsuke Nanto
Circulation Reports, Volume 2, pp 637-638; doi:10.1253/circrep.cr-20-0054

Abstract:
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
Akihiro Shirakabe, Masato Matsushita, Kazutaka Kiuchi, Hirotake Okazaki, Toru Inami, Tsutomu Takayasu, Miwako Asano, Akiko Nomura, Nobuaki Kobayashi, Fumitaka Okajima, et al.
Circulation Reports, Volume 2, pp 565-575; doi:10.1253/circrep.cr-20-0041

Abstract:
Background:Whether the dose of loop diuretics can be decreased by administration of a sodium-glucose cotransporter 2 (SGLT2) inhibitor in diabetic outpatients with compensated heart failure (HF) is unclear. Methods and Results:This study prospectively enrolled 60 diabetic outpatients with compensated HF. Patients were randomly divided into 2 groups: those administered the SGLT2 inhibitor empagliflozin (n=28) and those not (n=30). Changes in the daily dose of loop diuretics, blood sampling data, and urinary renal tubular biomarkers were evaluated 6 months after the intervention. The median (interquartile range) furosemide dose decreased significantly over the 6-month follow-up period in the empagliflozin group (from 40 [20–40] to 20 [10–20] mg), but not in the non-empagliflozin group (from 23 [20–40] to 40 [20–40] mg). Hemoglobin levels increased significantly in the empagliflozin group (from 13.2 [11.9–14.6] to 14.0 [12.7–15.0] g/dL). In addition, excretion of acetyl-β-D-glucosaminidase decreased significantly over the 6-month follow-up in the empagliflozin group (from 4.8 [2.6–11.7] to 3.3 [2.1–5.4] IU/L), especially in the group in which the dose of loop diuretics decreased (from 4.7 [2.5–14.8] to 3.3 [2.1–4.5] IU/L). Conclusions:Empagliflozin administration decreased the dose of loop diuretics and increased the production of erythropoietin, which may help prevent renal tubular injury in diabetic outpatients with HF.
Ayumu Fujioka, Kenji Yanishi, Keisuke Shoji, Yusuke Hori, Hirofumi Kawamata, Arito Yukawa, Isao Yokota, Satoshi Teramukai, Ayumu Yamada, Satoaki Matoba
Circulation Reports, Volume 2, pp 630-634; doi:10.1253/circrep.cr-20-0086

Abstract:
Background:Patients with thromboangiitis obliterans (TAO) can develop critical limb-threatening ischemia (CLTI) and require limb amputation. Smoking cessation and exercise therapy are recommended as standard treatments, and revascularization by bypass surgery or endovascular therapy (EVT) is required for patients with CLTI. However, there are many cases in which revascularization is difficult because of vascular characteristics, and the patency rate after revascularization remains unsatisfactory. Therapeutic angiogenesis using bone marrow-derived mononuclear cell (BM-MNC) implantation is used clinically, with many trials demonstrating long-term efficacy and safety of the technique in patients with CLTI, especially that caused by TAO. To expand the use of BM-MNCs implantation in clinical practice, further evidence is required in patients with CLTI caused by TAO. Methods and Results:This trial is a multicenter, prospective, non-randomized interventional trial of an Advanced Medicine B treatment approach. We aim to enroll 25 patients aged 20–80 years with Fontaine classification Stage III or IV, who will undergo BM-MNC implantation. The primary endpoint is the improvement in skin perfusion pressure of the target limb 180 days after BM-MNC implantation, whereas secondary endpoints are improvements in rest pain or ulcer size. We will also investigate rates of major or minor amputation, survival, and adverse events during follow-up. Conclusions:BM-MNC implantation is expected to be an efficacious and feasible treatment for patients with CLTI caused by TAO.
Masaharu Nakayama, Kazuya Takehana, Takahide Kohro, Tetsuya Matoba, Hiroyuki Tsutsui, Ryozo Nagai, on behalf of the IHE Cardiology Team and SEAMAT Committee
Circulation Reports, Volume 2, pp 587-616; doi:10.1253/circrep.cr-20-0077

Abstract:
Background:In the era of big data, the utilization and analysis of large amounts of clinical data are imperative. The standardized structured medical information exchange version 2 (SS-MIX2) is a standard data storage format used in Japan to share clinical data from various vendor-derived hospital information systems. This storage format is divided into 2 categories: standardized and extension storage. Although the standardized storage includes clinical data such as basic patient data, prescriptions, and laboratory results, all other data are stored in the extension storage, because their formats are not standardized. Methods and Results:In 2015, the Japanese Circulation Society developed the standard export data format (SEAMAT) for electrocardiography (ECG), ultrasound cardiography (UCG), and catheterization (CATH) data for the SS-MIX2 extension storage. Using physical examination and catheter report systems in accordance with the SEAMAT, specific cardiological data such as ECG, UCG, and CATH can be transferred to the SS-MIX2 extension storage, resulting in efficient secondary use of these data for research purposes. Conclusions:SEAMAT can aid in the effective establishment of a nationwide clinical database, and reduce tedious manual data input by clinicians and clinical research coordinators. Moreover, a program that enables the conversion of comma-separated data from information systems into SEAMAT can provide a useful and economical tool for transferring huge clinical data to the SS-MIX2.
Hiroyuki Nakayama, Yuji Nishimoto, Kozo Hotta, Yukihito Sato
Circulation Reports, Volume 2, pp 560-564; doi:10.1253/circrep.cr-20-0033

Abstract:
Background:Early intervention with enteral nutrition (EN) is the standard of care in many medical intensive care units (ICUs). However, few studies have addressed the use of early EN for critically ill patients in the cardiac ICU (CICU). In this study we explored the indications for early EN for patients admitted to a CICU. Methods and Results:This retrospective observational study included 63 consecutive patients admitted to the CICU who were diagnosed with cardiovascular disease. Early EN was initiated in these patients as per the hospital’s nutrition protocol. Mean Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores at admission were 18.8 and 9.1, respectively. All patients were admitted to the medical CICU with a diagnosis of cardiovascular disease and/or cardiopulmonary arrest. Enteral feeding was initiated in 59 patients (94%) within 5 days of admission. Fifty-two patients (83%) achieved the energy intake goal at Day 7 of their CICU admission either by enteral feeding or oral intake; 49 patients (78%) survived to time of discharge. The patients experienced several minor complications, including minor reflux (4 patients; 6%) and diarrhea (8 patients; 13%). None of the patients developed aspiration pneumonia or bowel ischemia. Conclusions:The present retrospective observational study indicates that early EN for critically ill patients in a medical CICU can be achieved safely with no major complications.
Osamu Tominaga, Eiichi Teshima, Atsuhiro Nakashima, Ryuji Tominaga
Circulation Reports, Volume 2, pp 635-636; doi:10.1253/circrep.cr-20-0059

Abstract:
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
Tadashi Nakajima, Akinori Oh, Shun Saita, Takuo Yoshida, Mitsuru Ohishi, Nobuhiro Nishigaki
Circulation Reports, Volume 2, pp 576-586; doi:10.1253/circrep.cr-20-0076

Abstract:
Background:Angiotensin II receptor blockers (ARBs) are widely used for the management of hypertension in Japan; however, comparative efficacy data within the ARB drug class remain limited. Methods and Results:This systematic literature review identified randomized controlled trials (RCT) indexed in PubMed and Ichushi in Japanese patients with hypertension receiving ARB monotherapy (azilsartan, candesartan cilexetil, irbesartan, losartan potassium, olmesartan medoxomil, telmisartan, valsartan) in at least 1 arm. Of 763 RCTs identified, 77 met the eligibility criteria; of which, 37 reported mean change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline in the office setting and were used to construct the network. A fixed-effects model (FEM) showed the effect of each drug vs. the reference, azilsartan. Using the FEM, the mean (95% credible interval) change from baseline in SBP/DBP for candesartan cilexetil, irbesartan, losartan potassium, olmesartan medoxomil, telmisartan, and valsartan was 3.8 (2.9–4.8)/2.6 (2.0–3.1), 4.8 (2.0–7.5)/3.7 (1.8–5.6), 3.0 (0.8–5.1)/1.9 (0.5–3.3), 3.2 (1.2–5.1)/2.7 (1.3–4.1), 3.2 (0.8–5.6)/2.0 (0.3–3.6), and 3.1 (1.1–5.1)/2.4 (1.1–3.8) mmHg, respectively. Conclusions:The results of this meta-analysis provide evidence that azilsartan has a more favorable efficacy profile than the other ARBs in reducing SBP and DBP.
Circulation Reports, Volume 2; doi:10.1253/circrep.cr-2-content10

The publisher has not yet granted permission to display this abstract.
Toshihiko Nishi, Yoshiyuki Tokuda, Akihito Tanaka, Kenji Furusawa, Yusuke Miki, Akihiro Tobe, Toyoaki Murohara, Akihiko Usui
Circulation Reports; doi:10.1253/circrep.cr-20-0060

Abstract:
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
Back to Top Top